CYP2C9 Cancer Research Results

CYP2C9, CYP2C9: Click to Expand ⟱
Source:
Type:
CYP2C9, cytochrome P450 enzyme
– CYP2C9 is involved in the metabolism of a range of xenobiotics, including several anticancer drugs, which can affect drug efficacy and toxicity.
– Although CYP2C9 is not traditionally considered an oncogene or tumor suppressor, its expression and genetic variants can influence patient responses to chemotherapy.
Scientific Papers found: Click to Expand⟱
1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, We find that oral intake of dietary materials would require heroic ingestion amounts and is not feasible. However, use of supplements of semi-purified apigenin in capsule form could reach target blood levels using amounts that are within the range cu
Half-Life∅, elimination half-life (T1/2) averaging 2.52 ± 0.56h
*BioAv↓, bioavailability is in the region of 30%
Dose∅, Blood and urine samples were taken following a meal consisting of 2g parsley/kg body weight–which was equivalent to ∼17mg of apigenin -> 28–337nmol/L at 6–10h after consumption
eff↑, Apigenin and quercetin enhance their own and each other’s bioavailability by downregulating the activity of ABC transporters
CYP1A2↓, status of apigenin as an inhibitor of CYP1A2, CYP2C9 and CYP3A4
CYP2C9↓,
CYP3A4↓,

5480- BM,    Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
- Human, Nor, NA
P450↓, Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
CYP3A4↓, B. monnieri reduced the catalytic activities of CYP3A4, CYP2C9 and CYP2C19 to less than 10% compared to the total activity (without inhibitor = 100%).
CYP2C9↓,

6137- CHr,    Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters
- in-vitro, NA, NA
CYP2C9↓, chrysin conjugates are strong inhibitors of certain biotransformation enzymes (e.g., CYP2C9) and transporters (e.g., OATP1B1, OATP1B3, OATP2B1, and BCRP) examined.
OATPs↓,
ABCG2↓,
BioEnh↝, simultaneous administration of chrysin-containing dietary supplements with medications needs to be carefully considered due to the possible development of pharmacokinetic interactions.

7769- IBC,    Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters
- in-vivo, NA, NA
*AntiCan↑, Isobavachalcone, a naturally occurring chalcone in Psoralea corylifolia, posses many biological properties including anticancer, antiplatelet, and antifungal.
*AntiAg↑,
*AntiFungal↑,
CYP2C9↓, isobavachalcone demonstrated broad-spectrum inhibitory effects against CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, UGT1A1, UGT1A9, UGT2B7 with IC50 values of 1.08-9.78 μM.
UGT1A↓,
CYP2D6↓,
CYP2E1↓,

8217- LCA,    Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice
- Study, Nor, NA
*CYP1A1↓, LCA significantly inhibited the activities of CYP1A2, 2C19, 2C8, 2C9 and 3A4 and exhibited weak inhibitory effects on CYP2E1 and CYP2D6.
*CYP2C19↓,
*CYP2C8↓,
*CYP2C9↓,
*CYP3A4↓,
*CYP2E1↓,
*CYP2D6↓,
*BioEnh↑, rediction results from the in vivo HDI risk experiments indicated that the AUCs of the CYP2C substrates increased by 2–398% when these drugs were co-administrated with LCA.
eff↑, low-dose liquorice or LCA may slightly increase the AUCs of these CYP substrates, which could potentially increase their efficacies in the treatment of cancer.


Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CYP2D6↓, 1,   UGT1A↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

CYP2E1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CYP3A4↓, 2,  

Barriers & Transport(tgid=15) ⓘ

OATPs↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioEnh↝, 1,   CYP1A2↓, 1,   CYP2C9↓, 4,   Dose∅, 1,   eff↑, 2,   Half-Life∅, 1,   P450↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

CYP2C19↓, 1,   CYP2C8↓, 1,   CYP2D6↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

CYP1A1↓, 1,   CYP2E1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CYP3A4↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioEnh↑, 1,   CYP2C9↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,  
Total Targets: 12

Scientific Paper Hit Count for: CYP2C9, CYP2C9
1 Apigenin (mainly Parsley)
1 Bacopa monnieri
1 Chrysin
1 Isobavachalcone
1 Licochalcone A
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1130  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page